Pictured: Jedd Wolchok & Alexander Rudensky
Announcement
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, January 6, 2014

Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.

Pictured: T cells
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 23, 2013

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

Pictured: Alexander Rudensky
Profile
By Celia Gittelson, BA  |  Monday, December 16, 2013

Alexander Rudensky’s research focuses on the role of a subset of white blood cells called regulatory T cells, which are believed to suppress the immune system’s ability to fight tumors.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the News
By Christina Pernambuco-Holsten, MA  |  Friday, December 6, 2013

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

Mouse glioblastoma tumor with phagocytic macrophages
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, October 15, 2013

Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.

Pictured: Pseudomonas aeruginosa
Snapshot
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, October 1, 2013

Memorial Sloan Kettering researchers have discovered how a common bacterium can evolve to become more mobile and easier to get rid of.

Pictured: Clostridium difficile
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, August 7, 2013

Information about the microbiome, the genes of all the microorganisms that naturally inhabit the human body, is leading to new approaches for treating infections in cancer patients.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Liang Deng
Profile
By Jim Stallard, MA, Writer/Editor  |  Friday, April 26, 2013

Physician-scientist Liang Deng cares for patients with melanoma and other skin cancers, and also conducts innovative research on poxviruses.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: BCG
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Friday, February 1, 2013

Researchers have shed light on how an important treatment for early-stage bladder cancer enters cancer cells to eradicate them.

Pictured: Prasad Adusumilli
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, January 3, 2013

A team from Memorial Sloan Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.

Pictured: Marcel R. M. van den Brink
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Friday, December 21, 2012

Memorial Sloan Kettering researchers have shown for the first time that administering a growth factor called interleukin-7 can help patients regenerate T cells more quickly after stem cell transplantation.

Center News

Stay Informed

Get the latest information about cancer care and research every month.